PETROS PHARMACEUTICALS INC (PTPI) Stock Price & Overview
NASDAQ:PTPI • US71678J2096
Current stock price
The current stock price of PTPI is 0.0664 USD. Today PTPI is down by -46.45%. In the past month the price decreased by -94.63%. In the past year, price decreased by -99.56%.
PTPI Key Statistics
- Market Cap
- 2.069M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -91.45
- Dividend Yield
- N/A
PTPI Stock Performance
PTPI Stock Chart
PTPI Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to PTPI. When comparing the yearly performance of all stocks, PTPI is a bad performer in the overall market: 99.96% of all stocks are doing better.
PTPI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PTPI. PTPI has a bad profitability rating. Also its financial health evaluation is rather negative.
PTPI Earnings
PTPI Forecast & Estimates
For the next year, analysts expect an EPS growth of 48.83% and a revenue growth 0.76% for PTPI
PTPI Groups
Sector & Classification
PTPI Financial Highlights
Over the last trailing twelve months PTPI reported a non-GAAP Earnings per Share(EPS) of -91.45. The EPS increased by 14.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -251.96% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PTPI Ownership
PTPI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.3 | 933.096B | ||
| JNJ | JOHNSON & JOHNSON | 20.88 | 586.064B | ||
| MRK | MERCK & CO. INC. | 22.3 | 285.388B | ||
| PFE | PFIZER INC | 8.91 | 151.312B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.43 | 121.598B | ||
| ZTS | ZOETIS INC | 16.69 | 49.875B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.92 | 26.593B | ||
| VTRS | VIATRIS INC | 5.39 | 15.555B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.24 | 11.634B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.093B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.204B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.893B | ||
| LGND | LIGAND PHARMACEUTICALS | 24.47 | 4.144B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PTPI
Company Profile
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. The company is headquartered in New York City, New York and currently employs 18 full-time employees. The company went IPO on 2020-12-02. The firm is pursuing access to its flagship prescription erectile dysfunction (ED) therapy, Stendra, via potential OTC designation. Stendra is a Phosphodiesterase - 5 (PDE - 5) inhibitor prescription medication for the treatment of ED and is the only patent protected PDE-5 inhibitor on the market. Stendra offers the ED therapeutic landscape a valuable addition as an oral ED therapy that may be taken once daily as early as approximately 15 minutes prior to sexual engagement, with or without food, when using the 100mg or 200mg dosing, subject to certain contraindications and limitations common among PDE-5 inhibitors. The company also markets its own line of medical devices intended for ED treatment through its subsidiaries, Timm Medical and PTV, including the VED systems marketed as Osbon ErecAid and PosTVac.
Company Info
IPO: 2020-12-02
PETROS PHARMACEUTICALS INC
1185 Avenue Of The Americas, 3Rd Floor, Suite 570
New York City NEW YORK 10036 US
CEO: John D. Shulman
Employees: 21
Phone: 19732420005
PETROS PHARMACEUTICALS INC / PTPI FAQ
What does PTPI do?
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. The company is headquartered in New York City, New York and currently employs 18 full-time employees. The company went IPO on 2020-12-02. The firm is pursuing access to its flagship prescription erectile dysfunction (ED) therapy, Stendra, via potential OTC designation. Stendra is a Phosphodiesterase - 5 (PDE - 5) inhibitor prescription medication for the treatment of ED and is the only patent protected PDE-5 inhibitor on the market. Stendra offers the ED therapeutic landscape a valuable addition as an oral ED therapy that may be taken once daily as early as approximately 15 minutes prior to sexual engagement, with or without food, when using the 100mg or 200mg dosing, subject to certain contraindications and limitations common among PDE-5 inhibitors. The company also markets its own line of medical devices intended for ED treatment through its subsidiaries, Timm Medical and PTV, including the VED systems marketed as Osbon ErecAid and PosTVac.
Can you provide the latest stock price for PETROS PHARMACEUTICALS INC?
The current stock price of PTPI is 0.0664 USD. The price decreased by -46.45% in the last trading session.
What is the dividend status of PETROS PHARMACEUTICALS INC?
PTPI does not pay a dividend.
How is the ChartMill rating for PETROS PHARMACEUTICALS INC?
PTPI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for PETROS PHARMACEUTICALS INC?
PETROS PHARMACEUTICALS INC (PTPI) operates in the Health Care sector and the Pharmaceuticals industry.
Would investing in PETROS PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PTPI.
What is the outstanding short interest for PETROS PHARMACEUTICALS INC?
The outstanding short interest for PETROS PHARMACEUTICALS INC (PTPI) is 0% of its float.